RAPT Therapeutics, Inc.
DelistedCIK 1673772fmd_1BHVWTB400N1GCTEZKVPDX6SBCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2025, 31 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (136)
- Net income
- (130)
- Free cash flow
- (83)
Latest quarter · Q3 FY2025
Millions- Operating income
- (19)
- Net income
- (18)
- Free cash flow
- (12)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
RAPT Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$136.1 million | -$127.1 million | 10-K 2025-03-06 · proof | |
| Net income | -$129.9 million | -$116.8 million | 10-K 2025-03-06 · proof | |
| Cash from operating activities | -$83.3 million | -$97 million | 10-K 2025-03-06 · proof | |
| Free cash flow | -$83.4 million | -$98.2 million | 10-K 2025-03-06 · proof | |
| Total assets | $240.3 million | $173.3 million | +38.7% | 10-K 2025-03-06 · proof |
| Total liabilities | $50.4 million | $26.3 million | +91.8% | 10-K 2025-03-06 · proof |
| Cash and cash equivalents | $169.7 million | $47.5 million | +257.5% | 10-K 2025-03-06 · proof |
- What was RAPT Therapeutics, Inc.'s operating income in fiscal 2024?
- RAPT Therapeutics, Inc. reported operating income of -$136.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$127.1 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was RAPT Therapeutics, Inc.'s net income in fiscal 2024?
- RAPT Therapeutics, Inc. reported net income of -$129.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$116.8 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was RAPT Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- RAPT Therapeutics, Inc. reported cash from operating activities of -$83.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$97 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was RAPT Therapeutics, Inc.'s free cash flow in fiscal 2024?
- RAPT Therapeutics, Inc. reported free cash flow of -$83.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$98.2 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are RAPT Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, RAPT Therapeutics, Inc. reported total assets of $240.3 million, against $173.3 million a year earlier (+38.7%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are RAPT Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, RAPT Therapeutics, Inc. reported total liabilities of $50.4 million, against $26.3 million a year earlier (+91.8%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are RAPT Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, RAPT Therapeutics, Inc. reported cash and cash equivalents of $169.7 million, against $47.5 million a year earlier (+257.5%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1673772&period_type=annual&limit=5"Information only, not investment advice.